Search Result

Results for "

MetS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Met/HGFR (192) 5-HT Receptor (2) Akt (7) Amino Acid Derivatives (16) Aminopeptidase (1) AMPK (1) Amyloid-β (2) Anaplastic lymphoma kinase (ALK) (13) Angiotensin Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (3) Apoptosis (55) Autophagy (16) Bacterial (6) Bcl-2 Family (1) Beta-secretase (1) Biochemical Assay Reagents (3) Bombesin Receptor (1) Bradykinin Receptor (1) Btk (1) c-Fms (1) c-Kit (11) Cannabinoid Receptor (1) Casein Kinase (1) Caspase (4) CCR (2) CDK (1) Checkpoint Kinase (Chk) (1) COX (2) CRFR (1) CXCR (1) Cytochrome P450 (1) Dipeptidyl Peptidase (1) Discoidin Domain Receptor (2) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (2) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (9) Elastase (1) Endogenous Metabolite (8) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (1) FAK (1) FGFR (3) FLT3 (14) Fluorescent Dye (2) Formyl Peptide Receptor (FPR) (2) Fungal (1) FXR (1) G-quadruplex (1) GCGR (1) Glutaminase (3) HDAC (3) Hemoglobin (1) HIF/HIF Prolyl-Hydroxylase (2) IGF-1R (1) iGluR (3) Influenza Virus (1) Insulin Receptor (2) Isotope-Labeled Compounds (9) JAK (1) JNK (1) Leukotriene Receptor (1) Lipoxygenase (1) MDM-2/p53 (1) MEK (1) MetAP (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (4) Mitosis (1) MMP (2) mRNA (1) mTOR (3) Neprilysin (2) Neurokinin Receptor (6) Neuropeptide Y Receptor (1) NF-κB (1) Opioid Receptor (13) P-glycoprotein (2) p38 MAPK (1) PARP (1) PDGFR (5) Phosphatase (1) PI3K (3) Polo-like Kinase (PLK) (1) Potassium Channel (3) PROTAC Linkers (1) PROTACs (7) Protease Activated Receptor (PAR) (1) RAD51 (3) Raf (1) Reactive Oxygen Species (ROS) (1) Reference Standards (14) RET (3) RIP kinase (1) ROS Kinase (10) SARS-CoV (1) Small Interfering RNA (siRNA) (5) Src (2) STAT (3) TAM Receptor (22) Target Protein Ligand-Linker Conjugates (3) TGF-β Receptor (1) TNF Receptor (1) Topoisomerase (3) Trk Receptor (4) TRP Channel (1) Tyrosinase (4) VEGFR (33)
By Research Areas:	Cancer (218) Cardiovascular Disease (10) Endocrinology (5) Infection (9) Inflammation/Immunology (16) Metabolic Disease (21) Neurological Disease (37)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (2) mRNA (1) Human Pre-designed siRNA Sets (2) siRNAs (5)

333

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: c-Met/HGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18309

MET kinase-IN-4	c-Met/HGFR VEGFR	Cancer
MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC₅₀ value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer .

HY-12019

SGX-523 5+ Cited Publications	c-Met/HGFR	Cancer
SGX523 is a exquisitely selective and ATP-competitive *MET* inhibitor. SGX523 potently inhibits MET with an IC₅₀ of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity .

HY-P990073

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a humanIgG4-kappa, *anti-MET* bispecific antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic agent .

HY-P99391

Telisotuzumab ABT-700	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-10949

SMER3	E1/E2/E3 Enzyme	Cancer
SMER3, a Rapamycin enhancer, is a selective Skp1-Cullin-F-box (SCF) ^Met30 ubiquitin ligase inhibitor. SMER3 enhances Rapamycin's growth inhibitory effect by inhibition of SCF ^Met30 .

HY-15456

NVP-BVU972	c-Met/HGFR	Cancer
NVP-BVU972 is an selective and potent *Met* inhibitor, with an IC₅₀ of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against *Met* with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer .

HY-162773

MET-IN-1	c-Met/HGFR	Cancer
MET-IN-1 (Compound 13) is an orally active *MET* inhibitor. MET-IN-1 has antitumor activity .

HY-175337

*c-Met* ligand-Linker Conjugate 2**	Target Protein Ligand-Linker Conjugates c-Met/HGFR	Cancer
c-Met ligand-Linker Conjugate 2 is a synthesized target protein ligand-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC c-Met degrader-6 (HY-175321). PROTAC c-Met degrader-6 is a *c-Met* PROTAC** degrader with anti-tumor activity ^{[1] ^.}

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-146884

MET kinase-IN-3	c-Met/HGFR VEGFR	Cancer
MET kinase-IN-3 (compound 8) is an orally active and potent *MET* inhibitor, with an IC₅₀ of 9.8 nM. MET kinase-IN-3 shows good and broad-spectrum antiproliferative activity against cancer cell lines .

HY-P99250

Onartuzumab 1 Publications Verification MetMAb	c-Met/HGFR	Cancer
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the *MET* receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .

HY-114357A

DS-1205b free base	TAM Receptor c-Met/HGFR Trk Receptor	Cancer
DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC₅₀ of 1.3 nM. DS-1205b free base also inhibits MER, *MET, and TRKA, with IC₅₀*s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo .

HY-162103

Axl-IN-18	TAM Receptor Apoptosis	Cancer
Axl-IN-18 (compound 25c) is a potent and selective type II AXL inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC₅₀=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC₅₀=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model .

HY-RS21337

Etv3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Etv3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Etv3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Etv3 Mouse Pre-designed siRNA Set A Etv3 Mouse Pre-designed siRNA Set A

HY-19642

Glesatinib MGCD265	TAM Receptor c-Met/HGFR	Cancer
Glesatinib (MGCD265) is an orally active, potent *MET/SMO* dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-19642A

Glesatinib hydrochloride 2 Publications Verification MGCD265 hydrochloride	TAM Receptor c-Met/HGFR	Cancer
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent *MET/SMO* dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-E70754

MET Y1230A Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230A is a mutant of MET. MET Y1230A Recombinant Human Active Protein Kinase is a recombinant MET Y1230A protein that can be used to study MET Y1230A-related functions .

HY-P6440

Met-12	Apoptosis Caspase	Others
Met-12 is a small peptide inhibitor of the Fas receptor. Met-12 can inhibit Fas receptor-mediated photoreceptor cell apoptosis, reduce Caspase activation. Met-12 can be used in the research of photoreceptor .

HY-E70756

MET Y1230D Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230D is a mutant of MET. MET Y1230D Recombinant Human Active Protein Kinase is a recombinant MET Y1230D protein that can be used to study MET Y1230D-related functions .

HY-E70758

MET Y1235D Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1235D is a mutant of MET. MET Y1235D Recombinant Human Active Protein Kinase is a recombinant MET Y1235D protein that can be used to study MET Y1235D-related functions .

HY-E70749

MET D1228N Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228N is a mutant of MET. MET D1228N Recombinant Human Active Protein Kinase is a recombinant MET D1228N protein that can be used to study MET D1228N-related functions .

HY-E70748

MET D1228H Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228H is a mutant of MET. MET D1228H Recombinant Human Active Protein Kinase is a recombinant MET D1228H protein that can be used to study MET D1228H-related functions .

HY-E70755

MET Y1230C Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230C is a mutant of MET. MET Y1230C Recombinant Human Active Protein Kinase is a recombinant MET Y1230C protein that can be used to study MET Y1230C-related functions .

HY-E70752

MET L1195V Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET L1195V is a mutant of MET. MET L1195V Recombinant Human Active Protein Kinase is a recombinant MET L1195V protein that can be used to study MET L1195V-related functions .

HY-E70757

MET Y1230H Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230H is a mutant of MET. MET Y1230H Recombinant Human Active Protein Kinase is a recombinant MET Y1230H protein that can be used to study MET Y1230H-related functions .

HY-E70751

MET G1163R Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET G1163R is a mutant of MET. MET G1163R Recombinant Human Active Protein Kinase is a recombinant MET G1163R protein that can be used to study MET G1163R-related functions .

HY-E70753

MET M1250T Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET M1250T is a mutant of MET. MET M1250T Recombinant Human Active Protein Kinase is a recombinant MET M1250T protein that can be used to study MET M1250T-related functions .

HY-E70750

MET F1200I Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET F1200I is a mutant of MET. MET F1200I Recombinant Human Active Protein Kinase is a recombinant MET F1200I protein that can be used to study MET F1200I-related functions .

HY-18696

AMG-337 1 Publications Verification	c-Met/HGFR Caspase Apoptosis	Cancer
AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC₅₀ values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .

HY-148279

*c-Met-IN-15*	c-Met/HGFR	Cancer
c-Met-IN-15 (compound S3) is a *c-Met* kinase** inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

HY-174384

MET Transcription-IN-1	c-Met/HGFR Apoptosis G-quadruplex	Cancer
MET Transcription-IN-1 (Compound C3) is an orally active MET transcription inhibitor. MET Transcription-IN-1 can efficiently bind and stabilize the G-quadruplex in the *MET* promoter region, thereby inhibiting *c-Met* expression. MET Transcription-IN-1 can also overcome drug resistance caused by specific *c-Met* mutations. MET Transcription-IN-1 is capable of inhibiting tumor cell proliferation, migration, and invasion, as well as inducing cell cycle arrest and apoptosis. MET Transcription-IN-1 has antitumor activity, and can be used in the research of tumors such as non-small cell lung cancer .

HY-174581

*Human MET* mRNA**	mRNA	Cancer
Human MET mRNA encodes the human MET proto-oncogene, receptor tyrosine kinase (MET) protein, a member of the receptor tyrosine kinase family. MET regulates many physiological processes including proliferation, scattering, morphogenesis and survival.

HY-149360

P-gb-IN-1	P-glycoprotein	Cancer
P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .

HY-150576

*c-Met-IN-13*	c-Met/HGFR	Cancer
c-Met-IN-13 is a potent *c-Met* inhibitor with an IC₅₀ value of 2.43 nM. c-Met-IN-13 shows excellent cytotoxicity for cancer cells. c-Met-IN-13 shows antiproliferative activity in a concentration- and time- dependent manner. c-Met-IN-13 has the potential for the research of cancer .

HY-15735

*c-Met* inhibitor 1** 1 Publications Verification	c-Met/HGFR	Cancer
c-Met inhibitor 1 is an orally active *c-Met* inhibitor. c-Met inhibitor 1 can inhibit *c-Met* phosphorylation with an IC₅₀ of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma .

HY-161353

*c-Met-IN-23*	P-glycoprotein c-Met/HGFR	Cancer
c-Met-IN-23 (Compound 12g) is a *c-Met* inhibitor (IC₅₀ = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent .

HY-W009215

*H-Met-Ala-Ser-OH* L-Met-L-Ala-L-Ser	Amino Acid Derivatives	Others
H-Met-Ala-Ser-OH (L-Met-L-Ala-L-Ser) is a tripeptide. H-Met-Ala-Ser-OH can act as a formyl receptor .

HY-RS04566

ETV3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ETV3 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ETV3 Human Pre-designed siRNA Set A ETV3 Human Pre-designed siRNA Set A

HY-15959

Savolitinib 5+ Cited Publications Volitinib; HMPL-504; AZD-6094	c-Met/HGFR	Cancer
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable *c-Met* inhibitor with IC₅₀s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity .

HY-149880

*c-Met-IN-18*	c-Met/HGFR	Cancer
c-Met-IN-18 is ATP competitive type-III c-MET inhibitor of WT and D1228V mutant c-MET. c-Met-IN-18 has inhibitory for WT/D1228V with an IC₅₀ value of 0.013/0.20 ^e.c-Met-IN-18 can be used for the research of c-MET driven cancers . c-Met-IN-18 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149510

MET/PDGFRA-IN-1	c-Met/HGFR Apoptosis PDGFR	Cancer
MET/PDGFRA-IN-1 (compound 8c) is a *MET* and PDGFRA protein inhibitor (IC₅₀: 36 μM for MET). MET/PDGFRA-IN-1 inhibits MET phosphorylation and induces cell apoptosis. MET/PDGFRA-IN-1 inhibits proliferation of MET-positive cells (IC₅₀s: 15.3, 19.0, 22.0, 25.6, 21.0, 31.5 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) .

HY-157387

*c-Met-IN-22*	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-22 (compound 51am) is an orally active inhibitor against *c-Met* with an IC₅₀ value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis .

HY-139132

Met-F-AEA	Apoptosis	Cancer
Met-F-AEA is a metabolically stable anandamine analogue. Met-F-AEA inhibits cell growth by activating apoptosis. Met-F-AEA has antitumor activity .

HY-131065

MET kinase-IN-2	c-Met/HGFR	Cancer
MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC₅₀ of 7.4 nM. MET kinase-IN-2 has antitumor activity .

HY-163006

*EGFR/c-Met-IN-1*	EGFR c-Met/HGFR	Cancer
EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of *EGFR/c-Met. The IC₅₀ for inhibiting EGFR ^L858R and c-Met* is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo .

HY-W008371S2

*Fmoc-Met-OH-d3*	Isotope-Labeled Compounds	Others
Fmoc-Met-OH-d₃ is the deuterium labeled Fmoc-Met-OH.

HY-168268

*c-Met-IN-26*	c-Met/HGFR	Cancer
c-Met-IN-26 (compound 1-170) is a potent inhibitor of *c-Met, with the IC₅₀* of 1.6 nM. c-Met-IN-26 palys an important role in cancer research .

HY-P4191A

Met-RANTES (human) acetate	CCR	Inflammation/Immunology
Met-RANTES (human) acetate is the acetate form of Met-RANTES (human) (HY-P4191). Met-RANTES (human) acetate is the antagonist for CCR1 and CCR5. Met-RANTES (human) acetate inhibits chemokines human MIP-1α and MIP-1β with IC₅₀ of 5 and 2 nM. Met-RANTES (human) acetate reduces bone destruction and ameliorates rats adjuvant-induced arthritis (AIA) .

HY-120908

*c-Met-IN-16*	c-Met/HGFR	Cancer
c-Met-IN-16 is a *c-Met* inhibitor that can be used for cancer research .

HY-W008371S

*Fmoc-Met-OH-15N*	Isotope-Labeled Compounds	Others
Fmoc-Met-OH- ¹⁵N is the ¹⁵N labeled Fmoc-Met-OH .

Cat. No.	Product Name

HY-L188

Anti-Brain Cancer Compound Library

1,844 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,844 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

HY-L039

Reprogramming Compound Library

2,717 compounds

Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.

MCE Reprogramming Compound Library contains a unique collection of 2,717 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.

HY-L016

Protein Tyrosine Kinase Compound Library

1,420 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,420 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L101

Anti-Liver Cancer Compound Library

2,503 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,503 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P990073

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a humanIgG4-kappa, *anti-MET* bispecific antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic agent .

HY-P99391

Telisotuzumab ABT-700	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P99250

Onartuzumab 1 Publications Verification MetMAb	c-Met/HGFR	Cancer
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the *MET* receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits *c-Met* receptor-mediated cancer cell proliferation, migration, and invasion .

HY-P99192

Emibetuzumab LY2875358	c-Met/HGFR	Cancer
Emibetuzumab (LY2875358) is a humanized bivalent *MET* antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent *MET* pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P991565

CE-355621	c-Met/HGFR	Cancer
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (K_D = 200 pM, IC₅₀ = 466 pM) in A549 cells and cyno c-Met (K_D = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .

HY-P990432

*Anti-HGFR/c-Met* Antibody**	Inhibitory Antibodies	Inflammation/Immunology
Anti-HGFR/c-Met Antibody is a humanized antibody expressed in CHO, targeting *HGFR/c-Met. The Anti-HGFR/c-Met* Antibody contains huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFR/c-Met Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991177

*Anti-c-Met/HGFR Antibody* RC-108 antibody	c-Met/HGFR	Cancer
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets *c-Met*. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991589

SFN68 NOV-1105	c-Met/HGFR	Cancer
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits *HGF/c-Met* interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .

HY-P991660

ARGX-111	c-Met/HGFR	Cancer
ARGX-111 is an afucosylated anti-MET antibody. ARGX-111 blocks HGF-dependent and -independent signaling, downregulating MET expression on the tumor cell surface. ARGX-111 depletes MET-expressing circulating tumor cells through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby inhibiting tumor metastasis. ARGX-111 depletes circulating tumor cells and inhibits bone and lung metastasis in an orthotopic mouse model of metastatic breast cancer. ARGX-111 is promising for research in breast cancer and other cancers .

HY-P990947

Tilatamig	EGFR	Inflammation/Immunology
HY-P990947 is an *EGFR/MET*-targeting Ig(G1 -κ_G1 -λ2) type human antibody .

HY-P990755

Pamvatamig	EGFR	Inflammation/Immunology
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P99217

Rilotumumab AMG 102	c-Met/HGFR	Cancer
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .

HY-P9977

Amivantamab 3 Publications Verification JNJ-61186372	EGFR	Cancer
Amivantamab (JNJ-61186372) is a human *EGFR-MET* bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P990661

SAIT-301	c-Met/HGFR	Inflammation/Immunology
SAIT-301 is a humanized antibody expressed in CHO cells, targeting *HGFR/c-Met*. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P9977A

Amivantamab (FUT8-KO)	EGFR	Cancer
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, *c-MET, HIF-1α, and VEGF*. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W016647

*For-Met-OH* N-Formylmethionine	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Bacterial
For-Met-OH (N-Formylmethionine) can be involved in the translation process of bacteria, chloroplasts, and mitochondria. For-Met-OH plays different roles in different species and organelles, such as promoting the formation of protein complexes in mitochondria and acting as a degradation signal in bacteria and yeast. The level of For-Met-OH is closely related to certain diseases, for example, For-Met-OH is a potential biomarker for metabolic disorders and poor prognosis in critically ill patients .

HY-P1904

*Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa*	Natural Products Animals Source classification	Others
Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa is a FMRF-like peptide from visceral and somatic muscles of the snail Helix aspersa. FMRF (Phe-Met-Arg-Phe) is a neuropeptide peptide consisting of 4 amino acid residues .

HY-N6797

Meleagrin	Infection Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Bacterial c-Met/HGFR Antibiotic
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead *c-Met* inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies .

HY-128454

Dimethyl trisulfide	Natural Products Microorganisms Liliaceae Classification of Application Fields Source classification Other Diseases Plants Endogenous metabolite Disease Research Fields A．Sativam L. var．Viviparum Regel	Endogenous Metabolite
Dimethyl trisulfide is an organic chemical compound and the simplest organic trisulfide found in garlic, onion, broccoli, and similar plants. Dimethyl trisulfide is a cyanide antidote. Dimethyl trisulfide formation requires the thermal degradation of Met .

HY-W015309

Decanoic acid 3 Publications Verification	Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Biological Pesticide Research Agricultural Research	iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of *c-Met* and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-W016647R

*For-Met-OH (Standard)* N-Formylmethionine (Standard)	Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Bacterial
For-Met-OH (Standard) (N-Formylmethionine (Standard)) is the analytical standard of For-Met-OH (HY-W016647). This product is intended for research and analytical applications. For-Met-OH (N-Formylmethionine) can be involved in the translation process of bacteria, chloroplasts, and mitochondria. For-Met-OH plays different roles in different species and organelles, such as promoting the formation of protein complexes in mitochondria and acting as a degradation signal in bacteria and yeast. The level of For-Met-OH is closely related to certain diseases; for example, For-Met-OH is a potential biomarker for metabolic disorders and poor prognosis in critically ill patients.

HY-P4196

Met-Enkephalin-Arg-Phe	Monophenols Source classification Phenols Endogenous metabolite	Opioid Receptor
Met-Enkephalin-Arg-Phe is a naturally occurring heptapeptide with analgesic activity .

HY-N10219

Dihydroaltenuene B	Infection Monophenols Microorganisms Classification of Application Fields Source classification Phenols Disease Research Fields	Tyrosinase Fungal
Dihydroaltenuene B is a potent mushroom tyrosinase inhibitor with an IC₅₀ of 38.33 µM. Dihydroaltenuene B shows the hydrogen bonding interactions between the 3-OH and 4’-OH and the His244, Met280 and Gly281 residues of tyrosinase .

HY-128454R

Dimethyl trisulfide (Standard)	Natural Products Microorganisms Liliaceae Source classification Plants Endogenous metabolite A．Sativam L. var．Viviparum Regel	Reference Standards Endogenous Metabolite
Dimethyl trisulfide (Standard) is the analytical standard of Dimethyl trisulfide. This product is intended for research and analytical applications. Dimethyl trisulfide is an organic chemical compound and the simplest organic trisulfide found in garlic, onion, broccoli, and similar plants. Dimethyl trisulfide is a cyanide antidote. Dimethyl trisulfide formation requires the thermal degradation of Met .

HY-W015309R

Decanoic acid (Standard)	Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-W012817

Methylhydroquinone	Natural Products Microorganisms Classification of Application Fields Source classification Other Diseases Disease Research Fields	COX
Methylhydroquinone is an orally active COX inhibitor with IC₅₀s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions .

HY-W012817R

Methylhydroquinone (Standard)	Natural Products Microorganisms Source classification	COX Reference Standards
Methylhydroquinone (Standard) is the analytical standard of Methylhydroquinone. This product is intended for research and analytical applications. Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions[1][2].

Cat. No.	Product Name	Chemical Structure

HY-W008371S2

*Fmoc-Met-OH-d3*
Fmoc-Met-OH-d₃ is the deuterium labeled Fmoc-Met-OH.

HY-W008371S

*Fmoc-Met-OH-15N*
Fmoc-Met-OH- ¹⁵N is the ¹⁵N labeled Fmoc-Met-OH .

HY-W008371S1

*Fmoc-Met-OH-13C5,15N*
Fmoc-Met-OH- ¹³C₅, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled Fmoc-Met-OH (HY-W008371). Fmoc-Met-OH is a Methionine (HY-13694) derivative .

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-50878S2

Crizotinib-d9

Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878S1

Crizotinib-d8

Crizotinib-d₈ (PF-02341066-d₈) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-50683S

JNJ-38877605-d1
JNJ-38877605-d1 (compound DO-2) is a highly selective MNNG HOS transforming (MET) inhibitor. JNJ-38877605-d1 is thought to diminish the formation of the Aldehyde Oxidase 1 inactive metabolite M3 .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-W750959

L-Methionine sulfoxide-13C

L-Methionine sulfoxide- ¹³C (H-Met(O)-OH- ¹³C) is the ¹³C-labeled L-Methionine sulfoxide (HY-W010104). L-Methionine sulfoxide is an orally active oxidation product of Methionine (HY-N0326). L-Methionine sulfoxide can be partially converted into Methionine in the body and participate in the synthesis of glutathione in the liver. L-Methionine sulfoxide provides the body with sulfur activity and can participate in the synthesis of proteins and sulfur-containing compounds .

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-W266188

Decanoic acid-13C

Decanoic acid- ¹³C is the ¹³C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

Cat. No.	Product Name		Classification